M. Karthick

The evolution of active targeting in cancer therapy: bridging molecular biomarkers and intelligent nanomedicine

Despite the success of present-day chemotherapy, the shortcomings in this treatment, such as the lack of tumor selectivity, systemic toxicity, multidrug resistances, and insufficient therapeutic effects, still pose a challenge for successful clinical management of cancer. Active targeting to address these challenges ha...